Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Chung Feng Huang; Hsing Tao Kuo; Te Sheng Chang; Ching Chu Lo; Chao Hung Hung; Chien Wei Huang; Lee Won Chong; Pin Nan Cheng; Ming Lun Yeh; Cheng Yuan Peng; Chien Yu Cheng; Jee Fu Huang; Ming Jong Bair; Chih Lang Lin; Chi Chieh Yang; Szu Jen Wang; Tsai Yuan Hsieh; Tzong Hsi Lee; Pei Lun Lee; Wen Chih Wu; Chih Lin Lin; Wei Wen Su; Sheng Shun Yang; Chia Chi Wang; Jui Ting Hu; Lein Ray Mo; Chun Ting Chen; Yi Hsiang Huang; Chun Chao Chang; Chia Sheng Huang; Guei Ying Chen; Chien Neng Kao; Chi Ming Tai; Chun Jen Liu; Mei Hsuan Lee; Pei Chien Tsai; Chia Yen Dai; Jia Horng Kao; Han Chieh Lin; Wang Long Chuang; Chi Yi Chen; Kuo Chih Tseng; Ming Lung Yu

doi:10.1038/s41598-021-03006-3

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

Chung Feng Huang, Hsing Tao Kuo, Te Sheng Chang, Ching Chu Lo, Chao Hung Hung, Chien Wei Huang, Lee Won Chong, Pin Nan Cheng, Ming Lun Yeh, Cheng Yuan Peng, Chien Yu Cheng, Jee Fu Huang, Ming Jong Bair, Chih Lang Lin, Chi Chieh Yang, Szu Jen Wang, Tsai Yuan Hsieh, Tzong Hsi Lee, Pei Lun Lee, Wen Chih WuChih Lin Lin, Wei Wen Su, Sheng Shun Yang, Chia Chi Wang, Jui Ting Hu, Lein Ray Mo, Chun Ting Chen, Yi Hsiang Huang, Chun Chao Chang, Chia Sheng Huang, Guei Ying Chen, Chien Neng Kao, Chi Ming Tai, Chun Jen Liu, Mei Hsuan Lee, Pei Chien Tsai, Chia Yen Dai, Jia Horng Kao, Han Chieh Lin, Wang Long Chuang, Chi Yi Chen, Kuo Chih Tseng, Ming Lung Yu

內科學科

研究成果: Article › 同行評審

16 引文斯高帕斯（Scopus）

摘要

The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir (GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry (TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12 weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110/3144), with 98.8%, 99.4% and 100% in patients receiving 8 weeks, 12 weeks, and 16 weeks of GLE/PIB respectively. The SVR12 rate in the treatment-naïve cirrhotic patients receiving 8 weeks of GLE/PIB was 98.2% (108/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE/PIB was 5.94 visits for patients treated with 8 weeks, significantly different from the patients treated with 12 weeks of GLE/PIB (6.90 visits). The results support the effectiveness and safety of GLE/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE/PIB regimen is effective and cost-saving.

原文	English
文章編號	23473
期刊	Scientific reports
卷	11
發行號	1
DOIs	https://doi.org/10.1038/s41598-021-03006-3
出版狀態	Published - 2021 12月

All Science Journal Classification (ASJC) codes

多學科

存取文件

10.1038/s41598-021-03006-3

其它文件與鏈接

引用此

Huang, C. F., Kuo, H. T., Chang, T. S., Lo, C. C., Hung, C. H., Huang, C. W., Chong, L. W., Cheng, P. N., Yeh, M. L., Peng, C. Y., Cheng, C. Y., Huang, J. F., Bair, M. J., Lin, C. L., Yang, C. C., Wang, S. J., Hsieh, T. Y., Lee, T. H., Lee, P. L., ... Yu, M. L. (2021). Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Scientific reports, 11(1), 文章 23473. https://doi.org/10.1038/s41598-021-03006-3

@article{2985e298dd744435982cf3bc19af71d5,

title = "Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan",

abstract = "The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir (GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry (TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12 weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110/3144), with 98.8%, 99.4% and 100% in patients receiving 8 weeks, 12 weeks, and 16 weeks of GLE/PIB respectively. The SVR12 rate in the treatment-na{\"i}ve cirrhotic patients receiving 8 weeks of GLE/PIB was 98.2% (108/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE/PIB was 5.94 visits for patients treated with 8 weeks, significantly different from the patients treated with 12 weeks of GLE/PIB (6.90 visits). The results support the effectiveness and safety of GLE/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE/PIB regimen is effective and cost-saving.",

author = "Huang, {Chung Feng} and Kuo, {Hsing Tao} and Chang, {Te Sheng} and Lo, {Ching Chu} and Hung, {Chao Hung} and Huang, {Chien Wei} and Chong, {Lee Won} and Cheng, {Pin Nan} and Yeh, {Ming Lun} and Peng, {Cheng Yuan} and Cheng, {Chien Yu} and Huang, {Jee Fu} and Bair, {Ming Jong} and Lin, {Chih Lang} and Yang, {Chi Chieh} and Wang, {Szu Jen} and Hsieh, {Tsai Yuan} and Lee, {Tzong Hsi} and Lee, {Pei Lun} and Wu, {Wen Chih} and Lin, {Chih Lin} and Su, {Wei Wen} and Yang, {Sheng Shun} and Wang, {Chia Chi} and Hu, {Jui Ting} and Mo, {Lein Ray} and Chen, {Chun Ting} and Huang, {Yi Hsiang} and Chang, {Chun Chao} and Huang, {Chia Sheng} and Chen, {Guei Ying} and Kao, {Chien Neng} and Tai, {Chi Ming} and Liu, {Chun Jen} and Lee, {Mei Hsuan} and Tsai, {Pei Chien} and Dai, {Chia Yen} and Kao, {Jia Horng} and Lin, {Han Chieh} and Chuang, {Wang Long} and Chen, {Chi Yi} and Tseng, {Kuo Chih} and Yu, {Ming Lung}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-03006-3",

language = "English",

volume = "11",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Huang, CF, Kuo, HT, Chang, TS, Lo, CC, Hung, CH, Huang, CW, Chong, LW, Cheng, PN, Yeh, ML, Peng, CY, Cheng, CY, Huang, JF, Bair, MJ, Lin, CL, Yang, CC, Wang, SJ, Hsieh, TY, Lee, TH, Lee, PL, Wu, WC, Lin, CL, Su, WW, Yang, SS, Wang, CC, Hu, JT, Mo, LR, Chen, CT, Huang, YH, Chang, CC, Huang, CS, Chen, GY, Kao, CN, Tai, CM, Liu, CJ, Lee, MH, Tsai, PC, Dai, CY, Kao, JH, Lin, HC, Chuang, WL, Chen, CY, Tseng, KC & Yu, ML 2021, 'Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan', Scientific reports, 卷 11, 編號 1, 23473. https://doi.org/10.1038/s41598-021-03006-3

TY - JOUR

T1 - Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

AU - Huang, Chung Feng

AU - Kuo, Hsing Tao

AU - Chang, Te Sheng

AU - Lo, Ching Chu

AU - Hung, Chao Hung

AU - Huang, Chien Wei

AU - Chong, Lee Won

AU - Cheng, Pin Nan

AU - Yeh, Ming Lun

AU - Peng, Cheng Yuan

AU - Cheng, Chien Yu

AU - Huang, Jee Fu

AU - Bair, Ming Jong

AU - Lin, Chih Lang

AU - Yang, Chi Chieh

AU - Wang, Szu Jen

AU - Hsieh, Tsai Yuan

AU - Lee, Tzong Hsi

AU - Lee, Pei Lun

AU - Wu, Wen Chih

AU - Lin, Chih Lin

AU - Su, Wei Wen

AU - Yang, Sheng Shun

AU - Wang, Chia Chi

AU - Hu, Jui Ting

AU - Mo, Lein Ray

AU - Chen, Chun Ting

AU - Huang, Yi Hsiang

AU - Chang, Chun Chao

AU - Huang, Chia Sheng

AU - Chen, Guei Ying

AU - Kao, Chien Neng

AU - Tai, Chi Ming

AU - Liu, Chun Jen

AU - Lee, Mei Hsuan

AU - Tsai, Pei Chien

AU - Dai, Chia Yen

AU - Kao, Jia Horng

AU - Lin, Han Chieh

AU - Chuang, Wang Long

AU - Chen, Chi Yi

AU - Tseng, Kuo Chih

AU - Yu, Ming Lung

PY - 2021/12

Y1 - 2021/12

N2 - The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir (GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry (TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12 weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110/3144), with 98.8%, 99.4% and 100% in patients receiving 8 weeks, 12 weeks, and 16 weeks of GLE/PIB respectively. The SVR12 rate in the treatment-naïve cirrhotic patients receiving 8 weeks of GLE/PIB was 98.2% (108/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE/PIB was 5.94 visits for patients treated with 8 weeks, significantly different from the patients treated with 12 weeks of GLE/PIB (6.90 visits). The results support the effectiveness and safety of GLE/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE/PIB regimen is effective and cost-saving.

AB - The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir (GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a nation-wide registry in Taiwan. The Taiwan HCV Registry (TACR) is a nation-wide platform organized and supervised by the Taiwan Association for the Study of the Liver. Data were analyzed for patients treated with GLE/PIB, including 3144 patients who had treatment outcome available. The primary endpoint was sustained virological response (SVR12, undetectable HCV RNA throughout 12 weeks of end-of-treatment). The overall SVR12 rate was 98.9% (3110/3144), with 98.8%, 99.4% and 100% in patients receiving 8 weeks, 12 weeks, and 16 weeks of GLE/PIB respectively. The SVR12 rate in the treatment-naïve cirrhotic patients receiving 8 weeks of GLE/PIB was 98.2% (108/110). The most common AEs were fatigue (7.5%), pruritus (6.7%) and dizziness (1.5%). The mean number of outpatient visits during the GLE/PIB was 5.94 visits for patients treated with 8 weeks, significantly different from the patients treated with 12 weeks of GLE/PIB (6.90 visits). The results support the effectiveness and safety of GLE/PIB treatment in real-world clinical practice, and provide further evidence that the shorter, 8-week GLE/PIB regimen is effective and cost-saving.

UR - http://www.scopus.com/inward/record.url?scp=85120912574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120912574&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-03006-3

DO - 10.1038/s41598-021-03006-3

M3 - Article

C2 - 34873250

AN - SCOPUS:85120912574

SN - 2045-2322

VL - 11

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 23473

ER -

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

摘要

All Science Journal Classification (ASJC) codes

存取文件

其它文件與鏈接

指紋

引用此